Injective:
less a single DEX, more the shared order book infrastructure other exchanges build on.
We tore apart Injective, a Layer-1 blockchain purpose-built for on-chain finance with disclosed founders and backing including Binance, across the same seven-category scorecard we've used throughout this series. From a genuinely distinctive architecture, a protocol-level, shared decentralized order book that other exchanges plug into as relayers, a recent (November 2025) MultiVM environment running EVM and WASM on one shared state, and a genuinely unusual, real weekly deflationary auction burning INJ against collected trading fees, to an honest complexity worth explaining directly rather than glossing over: Injective's own total value locked is deliberately small, cited between roughly $8 million and $21.5 million, because order depth here comes from professional trading firms rather than pooled capital, meaning the usual TVL comparison we've used throughout this series doesn't fit this specific model, and trading volume and revenue are the more appropriate gauges instead (roughly $34.4 billion in derivatives volume and $3.41 million in trailing-twelve-month exchange revenue); and landed on a score the marketing page won't show you.
Our take, up front: Injective is genuinely different from every other platform we've reviewed in this series: rather than being a single, unified exchange, it's a Cosmos-ecosystem Layer-1 blockchain purpose-built for on-chain finance, providing a protocol-level, shared decentralized central limit order book that other exchanges and applications, acting as relayers, build on top of and source orders into. Real, disclosed, credible founders: Eric Chen (CEO, a former researcher at Innovating Capital focused on trading strategies) and Albert Chon (CTO, a Stanford computer science graduate with prior experience at Amazon), with disclosed backing from major industry players including Binance. Real, genuinely distinctive, functioning incentive structure: relayers earn 40% of the trading fees they source into the shared order book, with the remaining 60% flowing to Injective. Real, genuinely distinctive, real deflationary mechanism: a weekly community auction where participants bid INJ for that week's collected trading-fee basket, with the winning bid burned. Real, genuinely distinctive, recent (November 2025) MultiVM environment running EVM and WASM on one shared state, letting both Ethereum-style and Cosmos-native applications interact with the same underlying liquidity. Real, native USDC and Circle's CCTP integration as of May 2026, and genuinely significant real-world regulatory developments: the first U.S.-regulated INJ futures product launched via Bitnomial in April 2026, with three INJ ETF filings already submitted. What we can't gloss over: a genuinely important nuance about how to actually evaluate this platform's scale. Injective's own total value locked is deliberately small, cited between roughly $8 million and $21.5 million across our sources, because order depth here comes from a decentralized set of professional trading firms and institutions rather than pooled capital, meaning TVL, the metric we've used as a primary liquidity signal throughout most of this series, simply doesn't fit this specific model. By the metrics that do fit, trading volume and revenue, Injective shows real, substantial activity: roughly $34.4 billion in derivatives volume and $888 million in spot volume since January 2025, and $3.41 million in Exchange module revenue over a trailing twelve months, reportedly placing it in the top ten among all Layer-1 blockchains by protocol revenue. Real, no disclosed security incident specific to Injective found in our research. We weighted all of it below.
Real, no disclosed security incident specific to Injective found in our research. Real, disclosed, named founders (Eric Chen, Albert Chon) with credible professional backgrounds, and disclosed backing from major industry players including Binance. Real, honest, standard caveat: audits reduce but don't eliminate smart contract risk. Real, we found less specific, named third-party audit-firm detail for Injective than for several other platforms in this series.
Pros
- No disclosed security incident specific to Injective found in our research
- Disclosed, credible founders and backers (Eric Chen, Albert Chon, Binance)
Cons
- Less specific, named audit-firm detail than we found for several other platforms in this series
Real, genuinely important nuance worth explaining directly: Injective's own total value locked is small, cited between roughly $8 million and $21.5 million across our sources, but this specific metric doesn't capture the platform's real scale, because order depth on its shared orderbook comes from professional trading firms and institutions rather than pooled liquidity. Real, by the metrics that do fit this specific model, trading volume and revenue, Injective shows real, substantial activity: roughly $34.4 billion in derivatives and $888 million in spot volume since January 2025, and Exchange module revenue of $3.41 million over a trailing twelve months, reportedly ranking it in the top ten among all Layer 1 blockchains by protocol revenue.
Pros
- $34.4B+ in derivatives volume since January 2025; real, substantial activity
- Top-ten Layer 1 by protocol revenue despite minimal locked capital
Cons
- TVL itself is genuinely small and not a fitting comparison point to other DEXs in this series
Real, genuinely distinctive architecture: rather than a single company operating a matching engine, Injective provides a protocol-level, shared decentralized central limit orderbook that other exchanges and applications, acting as relayers, build on top of and source orders into. Real, disclosed, functioning incentive structure: relayers earn 40% of the trading fees they source, with the remainder flowing to Injective. Real, genuinely distinctive, real deflationary mechanism: a weekly community auction where the winning INJ bid for that week's collected trading fees is burned.
Pros
- Genuinely distinctive shared, decentralized order-matching infrastructure
- Real, functioning weekly fee-auction burn mechanism
Cons
- Shared-infrastructure model means decentralization varies by which relayer you actually use
Real, genuinely distinctive, recent (November 2025) MultiVM environment running EVM and WASM on one shared state, letting both Ethereum-style and Cosmos-native applications interact with the same liquidity. Real, genuinely broad derivatives coverage, with roughly 80% crypto and 20% real-world-asset markets per one detailed source. Real, native USDC and Circle's CCTP integration as of May 2026.
Pros
- Distinctive MultiVM (EVM + WASM) architecture on one shared state
- Real-world-asset markets alongside crypto derivatives
- Native USDC and Circle CCTP integration
Cons
- MultiVM adoption is still early; capacity is ahead of current demand per one detailed source
Real, Injective itself functions primarily as underlying infrastructure that other exchanges and applications build on, meaning the actual end-user experience varies significantly depending on which specific front-end or relayer application you use, rather than being a single, consistent interface. Real, this shared-infrastructure model is a genuinely different value proposition than a single, unified consumer DEX.
Pros
- Multiple front-end options; genuine choice for users
Cons
- No single, consistent interface; experience varies by relayer/application chosen
Real, disclosed, functioning fee-sharing model between Injective and the relayers/exchanges that source trading activity. Real, disclosed real-world regulatory developments: the first U.S.-regulated INJ futures product launched via Bitnomial in April 2026, with three INJ ETF filings submitted.
Pros
- Disclosed, functioning 60/40 fee-sharing model with relayers
- Real regulatory milestones: U.S.-regulated futures, ETF filings submitted
Cons
- Actual fees paid depend on which specific relayer/front-end is used
Real, genuinely distinctive MultiVM (EVM + WASM) architecture. Real, genuinely distinctive weekly fee-auction burn mechanism. Real, native Circle USDC/CCTP integration and emerging regulated derivatives products.
Pros
- Distinctive MultiVM architecture; weekly burn auction
- Native Circle USDC/CCTP integration; regulated derivatives emerging
Cons
- None significant found in our research
Access via a specific relayer or front-end application built on Injective, and verify the official domain directly.
Since the actual trading experience depends on which specific front-end you use, research the particular application built on Injective you're considering separately, rather than assuming every Injective-based interface offers the same features or protections.
Genuinely distinctive infrastructure, worth judging by its own metrics rather than everyone else's.
Injective earns real credit for building something structurally different from every other platform in this series: rather than competing as one more exchange, it provides shared, decentralized order book infrastructure that other exchanges plug into, with disclosed founders, real institutional backing, and a genuinely distinctive MultiVM architecture that's still ahead of current demand. The most important thing we can offer here isn't really a score at all; it's the reminder that comparing Injective's TVL against Uniswap's or Hyperliquid's is comparing the wrong thing entirely. Judged by the metrics that actually fit this model, real trading volume and real protocol revenue, Injective is a genuinely substantial, functioning piece of infrastructure. Judged as a simple consumer DEX, it's harder to evaluate cleanly, because your actual experience depends entirely on which specific application you choose to use on top of it.
The scorecard above is deliberately general. Whether Injective is right for you depends heavily on which of these you already are.
The developer or professional trading firm who wants shared, decentralized order book infrastructure to build on
This is genuinely what Injective is built for, and where its real, distinctive value concentrates most heavily.
The trader interested in real-world-asset derivatives or MultiVM applications spanning EVM and Cosmos-native code
These are genuinely distinctive, real capabilities most other platforms in this series don't offer.
The trader willing to research a specific front-end or relayer application built on Injective before committing
Given the real, honest variation in end-user experience across applications, this step genuinely matters here.
The casual trader looking for one single, simple, consistent app the way most other DEXs in this series provide directly
Injective's shared-infrastructure model means there's no single, unified consumer experience by design.
The scorecard covers the headline judgment calls. These four tables cover the specifics we didn't want to bury in prose; what Injective actually is precisely, the TVL-vs-revenue nuance explained, the weekly burn auction mechanism, and Injective against the sovereign-appchain family we've reviewed so far.
What Injective actually is, precisely
| A typical DEX (e.g. Uniswap, Hyperliquid) | Injective | |
|---|---|---|
| What it is | A single exchange with its own interface | A Layer-1 blockchain providing shared order book infrastructure |
| Who provides liquidity | Pooled capital from users (LPs) or a single vault | Professional trading firms and institutions acting as market makers |
| Who you interact with | The exchange's own front-end | Any of several relayer applications built on top |
This distinction genuinely matters: reviewing Injective as if it were a single consumer DEX would miss what it's actually built to be.
Why TVL doesn't fit this model
| Metric | Figure |
|---|---|
| Total value locked | ~$8-21.5 million (varies by source and date) |
| Derivatives volume since Jan 2025 | ~$34.4 billion |
| Spot volume since Jan 2025 | ~$888 million |
| Trailing 12-month exchange revenue | $3.41 million (top 10 among all Layer 1s) |
A small TVL alongside genuinely large volume and revenue is the expected signature of this specific model, not a red flag on its own; order depth comes from professional market makers rather than pooled capital.
The weekly burn auction, explained
| Step | What happens |
|---|---|
| Fee collection | Trading fees collected across the ecosystem accumulate into a weekly basket |
| Auction | Community members bid INJ for the right to claim that week's basket |
| Settlement | The winning bidder receives the full basket of assets |
| Burn | The winning bid, paid in INJ, is permanently burned |
This creates real, ongoing deflationary pressure on INJ's supply, distinct from the fee-distribution models we've seen on ve(3,3)-style platforms like Curve and Aerodrome.
Injective against the sovereign-appchain family
| Injective | dYdX | Osmosis | Paradex | |
|---|---|---|---|---|
| Base layer | Cosmos SDK sovereign L1 | Cosmos SDK sovereign L1 | Cosmos SDK sovereign L1 | Starknet zk-appchain |
| Model | Shared orderbook infrastructure for other exchanges | Single, unified order-book exchange | Single, unified AMM exchange | Single, unified order-book exchange |
| Founding team | Disclosed (Eric Chen, Albert Chon) | Disclosed | Disclosed (Informal Systems, Cosmostation) | Disclosed (Anand Gomes) |
| Distinctive extra | MultiVM (EVM+WASM); weekly burn auction | Validator-distributed matching | Four pool types; live merger vote | ZK-based position privacy |
Injective is the only platform in this specific family that positions itself as infrastructure for other exchanges rather than as a single, unified trading venue itself.
We don't just want to hand you our number; we want to show you how it sits next to what other review desks and comparison sites have published. We've flagged one source as notably dated (October 2023) relative to our other, more current 2026 research, since Injective's own architecture has genuinely evolved substantially since then.
Our score lands moderately below the aggregated industry average; most sources describe Injective's infrastructure-layer model favorably without directly grappling with how it complicates a straightforward liquidity or UX comparison, while our methodology treats that added complexity as a genuine, if modest, scoring factor.
| Source | Score | Type |
|---|
Scores compiled by our editorial team from publicly available reviews as of August 2026. "Editorial estimate" means the outlet didn't publish a single numeric score, so we converted their published verdict and sentiment into a comparable 100-point figure. Verify current figures directly with each source before citing them elsewhere.
Technically both, but functionally it's closer to a Layer-1 blockchain than a single exchange. Injective provides a shared, protocol-level decentralized order book that other exchanges and applications build on top of as relayers, rather than being a single, unified trading venue itself.
Because order depth comes from professional trading firms and institutions acting as market makers rather than pooled user capital. This is expected for Injective's specific model; volume and revenue, not TVL, are the metrics that actually reflect its scale.
An environment, live since November 2025, running both EVM (Ethereum-style) and WASM (Cosmos-native) smart contracts on one shared state, letting applications from both ecosystems interact with the same underlying liquidity.
Trading fees collected across the ecosystem accumulate into a weekly basket. Community members bid INJ for the right to claim it; the winning bidder receives the assets, and their winning bid, paid in INJ, is permanently burned.
Eric Chen (CEO) and Albert Chon (CTO), with disclosed backing from major industry players including Binance.
We found no disclosed security incident specific to Injective in our research.
Yes, roughly 20% of Injective's derivatives markets are real-world-asset focused per one detailed source, alongside the roughly 80% crypto-native markets.
The first U.S.-regulated INJ futures product launched via Bitnomial in April 2026, and three INJ ETF filings have been submitted as of our research.
More Reviews
THORChain – DEX Review
Score: 46/100. Unmatched native cross-chain swaps, carrying 2021 hacks, a $200M 2025 crisis, and use as a laundering conduit.
Read More
Hyperliquid – DEX Review
Score: 73/100. Dominant perp DEX, but closed-source code and the JELLY delisting controversy are real, unresolved trust questions.
Read More
Vertex – DEX Review
Score: 62/100. Sophisticated cross-margin trading, reviewed mid-migration to a new chain with conflicting founder accounts.
Read More
Raydium – DEX Review
Score: 68/100. Solana's liquidity leader, carrying two confirmed incidents and a real, wide gap in third-party security ratings.
Read More